Today, WebMD released The Cutting Edge of Cancer a five-part investigative video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, The Cutting Edge of Cancer, supported by Cancer Treatment Centers of America®, highlights some of the most promising areas of medical innovation in cancer care, including early detection, immunotherapy, genomic research, and integrative medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579755-webmd-robin-roberts-cutting-edge-of-cancer/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced the winners of its 2016 Health Hero Awards (http://www.webmd.com/healthheroes/what-is-hero), recognizing individuals who are changing the healthcare landscape by meeting a health challenge and giving back to others. This year’s winners are Seth Rogen and Lauren Miller Rogen, Ed Damiano, PhD, Betty Ferrell, RN, PhD and Trisha Prabhu.
On November 3, 2016, an accomplished and inspiring lineup of presenters and performers will gather to honor the winners at the 3rd Annual WebMD Health Hero Awards gala, hosted by Good Morning America co-anchor Robin Roberts. This year’s presenters include David Krumholtz, Adam Savage, and Sarah Wynter, with musical performances by A Great Big World and Naturally 7.
To watch the red carpet arrivals as they happen live from the TimesCenter in New York City, follow WebMD on www.facebook.com/webmd beginning at 6:30 PM ET on November 3, and be sure to follow @WebMD on Instagram, Snapchat and Twitter for updates throughout the night with #HealthHeroes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579756-webmd-2016-health-hero-awards/
On World Mental Health Day, Janssen has announced the results of a pan-European research project: ‘Talking About Treatment in Schizophrenia: A Patient and Carer Survey’. The survey of 166 adults living with schizophrenia and 468 carers was conducted by the independent market research agency, Fieldwork International (part of Ipsos MORI), and explored awareness, feelings and preferences regarding treatment.
The survey, conducted across 12 countries in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Netherlands, Russia, Spain, Sweden, Switzerland and the UK), highlighted key factors affecting the peace of mind for carers, such as the impact of the condition on day‑to-day life, potential relapse/hospitalisation and getting support beyond medication. 94% stated they reminded the person they care for to take their medication and for 49% this happens often.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7947151-janssen-survey-carers-adults-schizophrenia/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
Sickle cell disease (SCD) is an inherited, lifelong chronic disorder affecting nearly 100,000 Americans and a growing global health problem that will touch nearly 30 percent more people globally in the next three decades. Though new approaches to managing SCD have led to improvements in diagnosis and supportive care, people living with the disease still have severe complications to overcome. Many are unable to access quality care and are limited by a lack of effective treatment options.
In an effort to identify unmet medical needs for people with SCD, the American Society of Hematology (ASH), along with other groups, issued the State of Sickle Cell Disease: 2016 Report, evaluating the disease in four priority areas — access to care, training and professional education, research and clinical trials, and global health. The report shows that significant improvements are needed across all areas and that, though patients are living longer, the system of care needs to change to ensure a better quality of life. To address these challenges, ASH launched the Sickle Cell Disease Coalition along with more than 20 other organizations who are issuing a call to action that will amplify the voice of the SCD community, promote SCD awareness, and transform SCD care both in the United States and around the globe.
To view the multimedia release go to:
http://www.multivu.com/players/English/7903251-american-society-hematology-sickle-cell-coalition/
Ethicon*, a trusted leader in advancing wound closure, announces the launch of STRATAFIX™ Spiral PDS Plus and STRATAFIX™ Spiral Monocryl Plus Knotless Tissue Control Devices. With the addition of these two new suture technologies to the STRATAFIX™ Family of Knotless Tissue Control Devices, Ethicon has established the most comprehensive and unmatched knotless suture offering available to surgeons in the U.S.
STRATAFIX™ Knotless Tissue Control Devices transforms the wound closure experience by providing unique advantages over traditional sutures. STRATAFIX™ sutures provide more strength and security, more consistency and more efficiency than traditional suturing. The portfolio of knotless sutures also enables surgeons to more easily manage tension and control tissue approximation with each pass during closure and eliminates the need to tie knots.
To view the multimedia release go to:
http://www.multivu.com/players/English/7889651-ethicon-new-stratafix-suture/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
On September 10, 2016, the nation’s leading reproductive health, rights, and justice organizations will host free music and cultural events that shine a light on the majority of Americans who support abortion rights and show how access to abortion benefits women, their families and ultimately, the country.
All Access, a series of high-energy concerts, is bringing top musical and comedic talent to Cleveland with four other events taking place simultaneously in Atlanta, Chicago, Miami, and Philadelphia. From dance parties to slam poetry contests, thousands more will participate in more than 30 smaller events across the country to show that abortion rights supporters are visible, active, and willing to speak up.
To view the multimedia release go to:
http://www.multivu.com/players/English/7869451-all-access-concert-supporting-abortion-access/
Today, WebMD released Path to a Breakthrough, a five-part original video series developed in partnership with Robin Roberts and her independent production company, Rock’n Robin Productions. Through compelling patient stories and insights from medical experts, Path to a Breakthrough sheds light on how medical innovations, including Precision Medicine, Immunotherapy, and Biologics, are providing doctors with powerful new tools to treat disease, alleviate symptoms, and in some cases, reverse the course of debilitating illness.
In this extraordinary new series, WebMD and Roberts share the stories of Cara, a 4-year-old girl who lost, then regained her ability to walk from the clues hidden in her genetic makeup; Trevor, a man diagnosed with stage IV Lymphoma in the prime of his life, and the doctor who helped him harness his own immune system for a nontoxic cancer treatment; Kevin, whose pain from dirt bike racing injuries was nothing compared to the excruciating pain of Rheumatoid Arthritis; Falisha, whose life-changing diagnosis of Multiple Sclerosis was alleviated by biologics; and Rebecca, whose debilitating Psoriasis led to blindness.
To view the multimedia release go to:
http://www.multivu.com/players/English/7579754-webmd-path-to-a-breakthrough/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
